Regeneron shoots again with odronextamab
The company hits an FDA-mandated enrolment target, but only in follicular lymphoma.
Will Roche's Perseverance pay off?
Giredestrant will soon become the first oral SERD to yield first-line data.
Astra stakes a claim for early camizestrant
But this adds another complexity, and has camizestrant really scored a first-line win?
Pivotal study designs revealed
Keenly awaited trials of ficerafusp alfa, Trodelvy and divarasib materialise.
Zai Lab looks towards an accelerated pathway
The company believes that its DLL3-targeting ADC could be fast-tracked despite the presence of Imdelltra.
More bad vibes kill off Merck’s TIGIT and Lag3
Merck ditches vibostolimab and favezelimab following huge pivotal programmes.
